We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · December 05, 2020

Entinostat Plus Pembrolizumab for Metastatic NSCLC Previously Treated With Anti–-PD-L1 Therapy

Clinical Cancer Research


Additional Info

Clinical Cancer Research
Entinostat Plus Pembrolizumab In Patients With Metastatic NSCLC Previously Treated With Anti-PD-(L)1 Therapy
Clin. Cancer Res 2020 Nov 17;[EPub Ahead of Print], MD Hellmann, PA Janne, M Opyrchal, N Hafez, LE Raez, DI Gabrilovich, F Wang, JB Trepel, MJ Lee, A Yuno, S Lee, S Brouwer, S Sankoh, L Wang, D Tamang, EV Schmidt, ML Meyers, SS Ramalingam, E Shum, P Ordentlich

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading